Comparison of the cardiac electrophysiologic effects of NE-10064 with sotalol and E-4031 and their modification by simulated ischaemia

Journal of Cardiovascular Pharmacology
M A McIntoshK A Kane

Abstract

The electrophysiologic effects of a new anti-arrhythmic agent NE-10064 were compared with known class III drugs, E-4031 and sotalol, in sheep Purkinje fibres paced at 1 Hz under normal and simulated ischaemic conditions. NE-10064 0.3-3 microM and sotalol 0.3-300 microM prolonged action potential duration at 90% of repolarization (APD90) and effective refractory period (ERP) concentration dependently without affecting APD50 under normal conditions. E-4031 0.3-300 microM prolonged APD50, APD90, and ERP concentration dependently. Percentage increases in APD90 of 20 +/- 6, 27 +/- 6, and 33 +/- 9 were calculated for NE-10064 3 microM, sotalol 300 microM, and E-4031 1 microM under normal conditions, respectively. The concentration-response curves for all three drugs were shifted to the right under simulated ischaemic conditions. The shift was more marked for NE-10064 and sotalol. Percentage increases in APD90 of 8 +/- 5, 13 +/- 2, and 23 +/- 4 were observed with NE-10064 3 microM, sotalol 300 microM, and E-4031 1 microM during simulated ischaemia. NE-10064 exhibits electrophysiologic characteristics similar to those of known class III agents. Its ability to prolong APD90 under normal conditions may explain its antiarrhythmic action i...Continue Reading

Citations

Jun 12, 2003·European Journal of Pharmacology·János TakácsJulius Gy Papp
Aug 10, 1999·European Journal of Pharmacology·Y XueK Hashimoto
Jan 19, 1999·Journal of Chromatography. B, Biomedical Sciences and Applications·J J BaoA Shuja
Feb 2, 2000·Proceedings of the Society for Experimental Biology and Medicine·R R BrooksD R Kostreva
Apr 16, 1998·The American Journal of Cardiology·R KaramA Moore
Apr 16, 1998·The American Journal of Cardiology·A J CammC M Pratt
Dec 22, 1999·Journal of Cardiovascular Pharmacology·X Q QiP Dorian
Jul 1, 1997·Journal of Cardiovascular Pharmacology and Therapeutics·P D WestT J Campbell
Aug 15, 2000·Journal of Cardiovascular Pharmacology·V Nand, S A Doggrell
Jun 27, 2021·European Journal of Pharmacology·Moawiah M Naffaa, Ola A Al-Ewaidat

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.